Innovation Pharma (Formerly known as Cellceutix)

231 articles with Innovation Pharma (Formerly known as Cellceutix)

• Innovation Pharmaceuticals Receives Pre-IND Response from FDA on COVID-19 TrialCompany finalizing Brilacidin protocol; clinical study anticipated to commence in 4Q2020

  11/2/2020

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today receipt of written feedback from the U.S. Food and Drug Administration (FDA) that is in general agreement with the Company’s planned clinical trial for Brilacidin, a defensin-mimetic drug candidate, for the treatment of COVID-19. The FDA response completes the Pre-Investigational New Drug (Pre-IND) process. The FDA provided f

• Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19

  10/2/2020

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that earlier this week the Company submitted a pre-IND meeting request to the FDA in advance of a planned study of Brilacidin, a defensin-mimetic drug candidate, for the treatment of COVID-19. The request for the pre-IND meeting follows the FDA guidance issued in May 2020, “COVID-19 Public Health Emergency: General Consideratio

• Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

  8/4/2020

  Brilacidin is showing consistent and robust antiviral activity across the viral lifecycle in human lung and Vero cells; potential as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected

• Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line

  7/20/2020

  Company Considering Conducting In Vitro Testing Combining Brilacidin with Remdesivir™

• Innovation Pharmaceuticals – Clinical Trial Testing of Brilacidin Against SARS-CoV-2 (COVID-19) Targeted to Commence Q4 2020

  7/13/2020

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned clinical trial testing of Brilacidin, administered intravenously (IV), for the treatment of COVID-19. The exigencies of the pandemic coupled with Brilacidin’s multiple therapeutic properties – its anti-viral SARS-CoV-2 activity, its anti-inflammatory potential to abate the COVID-19 associated cytokine

• 

  Biopharma Update on the Novel Coronavirus: July 13

  7/13/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.

• In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial

  7/7/2020

  The Company also reports that all preferred shares and warrants outstanding have been exercised, establishing a cash balance of approximately $6 Million as of June 30, 2020

• Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line

  6/17/2020

  Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties against SARS-CoV-2

• Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic

  6/11/2020

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week. The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the curr

• Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line

  5/26/2020

  Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2

• Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity

  5/19/2020

  Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19

• 

  Biopharma Update on the Novel Coronavirus: May 19

  5/19/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.

• Inhibitory Effect of Innovation Pharmaceuticals’ Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute

  5/5/2020

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report the Company has executed a Material Transfer Agreement with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19.

• Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4

  4/27/2020

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been informed by researchers at the U.S. Regional Biocontainment Laboratory (RBL) that continued coronavirus (COVID-19) testing of Brilacidin, the Company’s defensin-mimetic drug candidate, is scheduled to begin the week of May 4. Concurrently, the Company is prioritizing Brilacidin’s clinical developmen

• Innovation Pharmaceuticals in Discussions to Advance Brilacidin into Human Trials Against COVID-19

  4/6/2020

  Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic. Their interest in Brilacidin as a treatment for COVID-

• Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions

  3/17/2020

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the Material Transfer Agreement (MTA) signed with a leading public health-focused U.S. university and top coronavirus expert. Under the terms of the confidential agreement, virologists plan to evaluate the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, t

• U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week

  3/10/2020

  Innovation Pharmaceuticals is pleased to inform shareholders that management has been advised testing of Brilacidin, the Company’s flagship defensin mimetic drug candidate, as a novel experimental treatment against the latest coronavirus is scheduled to commence at one of the 12 U.S.

• Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19

  2/27/2020

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced the Company signed a Material Transfer Agreement with one of the country’s 12 Regional Biocontainment Labs to research its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus treatment.

• Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus  (COVID-19)

  2/24/2020

  WAKEFIELD, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company submitted a Material Transfer Agreement (MTA) with a leading U.S.-based virology laboratory to research its lead defensin mimetic drug candidate, Brilacidin as a potential novel coronavirus treatment. Brilacidin has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in mul

• Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment

  2/18/2020

  “Defensins are conceptually ideal for defense against different viral infections” WAKEFIELD, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company is exploring its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus treatment. Over the last few weeks, the Company has received inquiries asking about Brilacidin’s potential to treat the Coronavirus g